Compounded semaglutide with B12: what adding the vitamin changes

What this comes down to

• No randomized trial tests semaglutide or tirzepatide combined with B12. The same filter finds 41 trials of semaglutide with metformin.
• Cyanocobalamin injection is approved for B12 deficiency caused by malabsorption. Nothing in its approval concerns nausea from another drug.
• A compounded drug that is essentially a copy of a commercially available one falls outside the 503A exemption unless a prescriber has determined that the change makes a significant difference for that specific patient.
• The FDA's guidance says a lower price is not sufficient to establish that a compounded product is not essentially a copy.

What has been tested

Nothing, in the sense that matters. Search PubMed for semaglutide or tirzepatide alongside any form of B12 and eleven records come back, none of them a randomized trial. Run the identical trial filter on semaglutide with metformin — a genuinely studied pairing — and it returns 41.

(semaglutide[tiab] OR tirzepatide[tiab]) AND ("vitamin B12"[tiab] OR cyanocobalamin[tiab] OR cobalamin[tiab]) AND "randomized controlled trial"[pt] AND "humans"[mh]

Nausea in the first weeks is the reason usually given for the vitamin, and it has never been tested in this combination. Cyanocobalamin injection is approved for vitamin B12 deficiency caused by malabsorption, and its label's own view is that requirements above normal for other reasons can usually be met by a tablet^[2]. What the vitamin does on its own is a separate question.

The rule an added ingredient runs into

A pharmacy compounding under section 503A loses the exemption if it regularly compounds drugs that are essentially copies of a commercially available drug product. The statute carves out one exception, quoted in the FDA's guidance on the provision^[1].

“the term 'essentially a copy of a commercially available drug product' does not include a drug product in which there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the comparable commercially available drug.”

^[1]

Read the conditions in that sentence rather than the permission. The change has to be made for an identified individual patient. The difference has to be significant for that patient. The prescriber has to be the one who determined it. And the FDA's guidance says the determination should be documented on the prescription, specifically enough to name the change and the difference it produces.

“This is to ensure that compounders do not evade the limits in this section by making relatively small changes to a compounded drug product and then offering the drug to the general public without regard to whether a prescribing practitioner has determined that the change produces for the patient a significant difference.”

^[1]

Why this analysis is live again

The copy rule only bites when the approved drug is commercially available. Through the 2023 to 2025 shortage, it largely wasn't. The FDA's shortage index carries 70 entries marked currently in shortage and four marked resolved, and neither semaglutide injection nor tirzepatide injection is on it^[3]. Liraglutide injection is on it, which is what makes that absence mean something.

So the approved products are available, and a compounded version of one of them is being measured against the copy rule rather than against a shortage exemption. That shift is why the question is being asked again now, and it is the background to the compounded versus brand question generally.

How it is priced where we have found it

Four lines on our roster are a GLP-1 sold with B12 in it, at $189 and $409 a month. Some of them come from a seller that also publishes a price for the same drug without the vitamin, which makes the two impossible to compare on the seller's own page. WePeptideRx and June Health are the two we have read.

GLP-1 with B12, on the sellers we have read first-hand

Whatever the analysis comes out to, the product is still a compounded one. It isn't a generic and it isn't FDA reviewed for safety, effectiveness or quality before it's sold^[5], and the agency lists a company claiming that a compounded drug is the same as an approved one among its telehealth red flags^[4]. Adding a vitamin does not change either of those.

Questions people actually ask

Sources

Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.

1. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2018. Source · Document dated January 2018
   The statutory carve-out quoted verbatim; the agency's statement that the limits exist so compounders do not evade them with relatively small changes offered to the general public; the requirement that a prescriber's determination be documented on the prescription; and the statement that a lower price is not sufficient to establish that a product is not essentially a copy.
2. Cyanocobalamin injection, USP — FDA prescribing information. U.S. Food and Drug Administration, Structured Product Labeling, 2025. Source · Document dated June 2025
   The approved indication is vitamin B12 deficiency due to malabsorption, and the label states that requirements above normal can usually be met with oral supplementation. Nothing in the approved indication concerns nausea caused by another drug.
3. FDA Drug Shortages: current and resolved drug shortages. U.S. Food and Drug Administration, accessdata, 2026. Source ·
   The server-rendered index table carried 70 entries marked currently in shortage and four marked resolved. Neither semaglutide injection nor tirzepatide injection appears; liraglutide injection is currently in shortage, which is the control proving the table covers this drug class.
4. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026. Source · Document dated September 2026
   Unapproved versions of GLP-1 drugs do not undergo FDA review for safety, effectiveness and quality before they are marketed, and the agency's telehealth red flags include a company claiming a compounded drug is the same as an FDA-approved drug.
5. Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025
   Compounded drugs are not FDA approved, a compounded drug is not a generic, and consumers buying through telehealth platforms may not know the identity of the compounder that produced the drug.